Vitamin D treatment in multiple sclerosis

Journal of the Neurological Sciences

Volumn 286, Issue 1-2, 2009, Pages 104-108

  Myhr, Kjell Morten ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Disease modifying; Multiple sclerosis; Prevention; Treatment; Vitamin D

Indexed keywords

CALCITRIOL; GADOLINIUM; HLA ANTIGEN CLASS 2; VITAMIN D; VITAMIN D RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONTRAST ENHANCEMENT; DEMYELINATING DISEASE; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; ENVIRONMENTAL FACTOR; FEMALE; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HUMAN; MALE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREGNANCY; PRIORITY JOURNAL; RELAPSE; REMISSION; RISK FACTOR; RISK REDUCTION; SEASONAL VARIATION; SKIN COLOR; SUN EXPOSURE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

ANIMALS; HUMANS; MULTIPLE SCLEROSIS; VITAMIN D;

EID: 70349780578     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.05.002     Document Type: Article

References (82)

1. Compston A., and Coles A. Multiple sclerosis. Lancet 372 (2008) 1502-1517
2. Ascherio A., and Munger K. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol 61 (2007) 504-513
3. Smolders J., Damoiseaux J., Menheere P., and Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 194 (2008) 7-17
4. Ascherio A., and Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol 28 (2008) 17-28
5. Cantorna M.T., Hayes C.E., and DeLuca H.F. 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 93 (1996) 7861-7864
6. Soilu-Hänninen M., Airas L., Mononen I., Heikkilä A., Viljanen M., and Hänninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 11 (2005) 266-271
7. van der Mei I.A., Ponsonby A.L., Dwyer T., Blizzard L., Taylor B.V., Kilpatrick T., et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 254 (2007) 581-590
8. Burton J.M., Kimball S.M., Vieth R., Bar-Or A., Dosch H.M., Thibault L., et al. A phase I/II dose escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis. Mult Scler 14 Suppl 1 (2008) 34
9. Moore C.E., Murphy M.M., and Holick M.F. Vitamin D intakes by children and adults in the United States differ among ethnic groups. J Nutr 135 (2005) 2478-2485
10. Holick M.F. The vitamin D epidemic and its health consequences. J Nutr 135 (2005) 2739-2748
11. Christakos S., Dhawan P., Liu Y., Peng X., and Porta A. New insights into the mechanisms of vitamin D action. J Cell Biochem 88 (2003) 695-705
12. Holick M.F. Resurrection of vitamin D deficiency and rickets. J Clin Invest 116 (2006) 2062-2072
13. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C., Dietrich T., and Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84 (2006) 18-28
14. Vieth R., Chan P.C., and MacFarlane G.D. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 73 (2001) 288-294
15. Heaney R.P., Davies K.M., Chen T.C., Holick M.F., and Barger-Lux M.J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 77 (2003) 204-210
16. Hathcock J.N., Shao A., Vieth R., and Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 85 (2007) 6-18
17. Cannell J.J., and Hollis B.W. Use of vitamin D in clinical practice. Altern Med Rev 13 (2008) 6-20
18. Garcion E., Wion-Barbot N., Montero-Menei C.N., Berger F., and Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 13 (2002) 100-105
19. Provvedini D.M., Tsoukas C.D., Deftos L.J., and Manolagas S.C. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 221 (1983) 1181-1183
20. Veldman C.M., Cantorna M.T., and DeLuca H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 374 (2000) 334-338
21. Dong X., Lutz W., Schroeder T.M., Bachman L.A., Westendorf J.J., Kumar R., et al. Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc Natl Acad Sci U S A 102 (2005) 16,007-16,012
22. Muthian G., Raikwar H.P., Rajasingh J., and Bright J.J. 1,25 dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J Neurosci Res 83 (2006) 1299-1309
23. Acheson E.D., Bachrach C.A., and Wright F.M. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr Scand 35 (1960) 132-147 (Suppl)
24. Sutherland J.M., Tyrer J.H., and Eadie M.J. The prevalence of multiple sclerosis in Australia. Brain 85 (1962) 149-164
25. van der Mei I.A., Ponsonby A.L., Blizzard L., and Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 20 (2001) 168-174
26. Kurtzke J.F. On the fine structure of the distribution of multiple sclerosis. Acta Neurol Scand 43 (1967) 257-282
27. Freedman D.M., Dosemeci M., and Alavanja M.C. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup Environ Med 57 (2000) 418-421
28. Goldacre M.J., Seagroatt V., Yeates D., and Acheson E.D. Skin cancer in people with multiple sclerosis: a record linkage study. J Epidemiol Community Health 58 (2004) 142-144
29. van der Mei I.A., Ponsonby A.L., Dwyer T., Blizzard L., Simmons R., Taylor B.V., et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 327 (2003) 316
30. Kampman M.T., Wilsgaard T., and Mellgren S.I. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol 254 (2007) 471-477
31. Islam T., Gauderman W.J., Cozen W., and Mack T.M. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 69 (2007) 381-388
32. Antonovsky A., Leibowitz U., Smith H.A., Medalie J.M., Balogh M., Kats R., et al. Epidemiologic study of multiple sclerosis in Israel. I. An overall review of methods and findings. Arch Neurol 13 (1965) 183-193
33. Cendrowski W., Wender M., Dominik W., Flejsierowicz Z., Owsianowski M., and Popiel M. Epidemiological study of multiple sclerosis in western Poland. Eur Neurol 2 (1969) 90-108
34. Munger K.L., Zhang S.M., O'Reilly E., Hernán M.A., Olek M.J., Willett W.C., et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 62 (2004) 60-65
35. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., and Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296 (2006) 2832-2838
36. Nieves J., Cosman F., Herbert J., Shen V., and Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44 (1994) 1687-1692
37. Mahon B.D., Gordon S.A., Cruz J., Cosman F., and Cantorna M.T. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 134 (2003) 128-132
38. Ozgocmen S., Bulut S., Ilhan N., Gulkesen A., Ardicoglu O., and Ozkan Y. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab 23 (2005) 309-313
39. Soilu-Hänninen M., Laaksonen M., Laitinen I., Erälinna J.P., Lilius E.M., and Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact PTH levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 79 (2008) 152-157
40. Smolders J., Menheere P., Kessels A., Damoiseaux J., and Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 14 (2008) 1220-1224
41. Tremlett H., van der Mei I., Pittas F., Blizzard L., Paley G., Mesaros D., et al. Monthly ambient sunlight, vitamin D, infections and relapse rates in multiple sclerosis. Mult Scler 14 Suppl 1 (2008) 203
42. Woolmore J.A., Stone M., Pye E.M., Partridge J.M., Boggild M., Young C., et al. Studies of associations between disability in multiple sclerosis, skin type, gender and ultraviolet radiation. Mult Scler 13 (2007) 369-375
43. Hanwell H.E., Vieth R., Bar-Or A., Sadovnick D., Arnold D., and Banwell B. Serum 25-hydroxyvitamin D status as a determinant of MS outcome following an initial demyelinating event in children. Mult Scler 14 Suppl 1 (2008) 6
44. Stamp T.C., and Round J.M. Seasonal changes in human plasma levels of 25-hydroxyvitamin D. Nature 247 (1974) 563-565
45. Maxwell J.D. Seasonal variation in vitamin D. Proc Nutr Soc 53 (1994) 533-543
46. Wüthrich R., and Rieder H.P. The seasonal incidence of multiple sclerosis in Switzerland. Eur Neurol 3 (1970) 257-264
47. Bamford C.R., Sibley W.A., and Thies C. Seasonal variation of multiple sclerosis exacerbations in Arizona. Neurology 33 (1983) 697-701
48. Auer D.P., Schumann E.M., Kümpfel T., Gössl C., and Trenkwalder C. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 47 (2000) 276-277
49. Ogawa G., Mochizuki H., Kanzaki M., Kaida K., Motoyoshi K., and Kamakura K. Seasonal variation of multiple sclerosis exacerbations in Japan. Neurol Sci 24 (2004) 417-419
50. Rovaris M., Comi G., Sormani M.P., Wolinsky J.S., Ladkani D., and Filippi M. Effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis. Ann Neurol 49 (2001) 415-416
51. Killestein J., Rep M.H., Meilof J.F., Adèr H.J., Uitdehaag B.M., Barkhof F., et al. Seasonal variation in immune measurements and MRI markers of disease activity in MS. Neurology 58 (2002) 1077-1080
52. Sadovnick A.D., and Yee I.M. Season of birth in multiple sclerosis. Acta Neurol Scand 89 (1994) 190-191
53. Willer C.J., Dyment D.A., Sadovnick A.D., Rothwell P.M., Murray T.J., Ebers G.C., et al. Timing of birth and risk of multiple sclerosis: population based study. BMJ 330 (2005) 120
54. Tremlett H.L., and Devonshire V.A. Does the season or month of birth influence disease progression in multiple sclerosis?. Neuroepidemiology 26 (2006) 195-198
55. Runmarker B., and Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 118 (1995) 253-261
56. Confavreux C., Hutchinson M., Hours M.M., Cortinovis-Tourniaire P., and Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 339 (1998) 285-291
57. Verhaeghe J., and Bouillon R. Calciotropic hormones during reproduction. J Steroid Biochem Mol Biol 41 (1992) 469-477
58. Schwartz G.G. Hypothesis: calcitriol mediates pregnancy's protective effect on multiple sclerosis. Arch Neurol 50 (1993) 455
59. Sicotte N.L., Liva S.M., Klutch R., Pfeiffer P., Bouvier S., Odesa S., et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 52 (2002) 421-428
60. Spach K.M., and Hayes C.E. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol 175 (2005) 4119-4126
61. Fukazawa T., Yabe I., Kikuchi S., Sasaki H., Hamada T., Miyasaka K., et al. Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J Neurol Sci 166 (1999) 47-52
62. Niino M., Fukazawa T., Yabe I., Kikuchi S., Sasaki H., and Tashiro K. Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J Neurol Sci 177 (2000) 65-71
63. Tajouri L., Ovcaric M., Curtain R., Johnson M.P., Griffiths L.R., Csurhes P., et al. Variation in the vitamin D receptor gene is associated with multiple sclerosis in an Australian population. J Neurogenet 19 (2005) 25-38
64. Steckley J.L., Dyment D.A., Sadovnick A.D., Risch N., Hayes C., and Ebers G.C. Genetic analysis of vitamin D related genes in Canadian multiple sclerosis patients. Canadian Collaborative Study Group. Neurology 54 (2000) 729-732
65. Yeo T.W., Maranian M., Singlehurst S., Gray J., Compston A., and Sawcer S. Four single nucleotide polymorphisms from the vitamin D receptor gene in UK multiple sclerosis. J Neurol 251 (2004) 753-754
66. Partridge J.M., Weatherby S.J., Woolmore J.A., Highland D.J., Fryer A.A., Mann C.L., et al. Susceptibility and outcome in MS: associations with polymorphisms in pigmentation-related genes. Neurology 62 (2004) 2323-2325
67. Smolders J., Damoiseaux J., Menheere P., Tervaert J.W., and Hupperts R. Fok-I vitamin D receptor gene polymorphism (rs10735810) and vitamin D metabolism in multiple sclerosis. J Neuroimmunol 207 (2009) 117-121
68. Niino M., Kikuchi S., Fukazawa T., Yabe I., and Tashiro K. No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MS. J Neuroimmunol 127 (2002) 177-179
69. Ramagopalan S.V., Maugeri N.J., Handunnetthi L., Lincoln M.R., Orton S.M., Dyment D.A., et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet (2009) e1000369 Electronic publication.
70. Orton S.M., Morris A.P., Herrera B.M., Ramagopalan S.V., Lincoln M.R., Chao M.J., et al. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr 88 (2008) 441-447
71. Torkildsen Ø., Knappskog P.M., Nyland H.I., and Myhr K.M. Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Arch Neurol 65 (2008) 809-811
72. Mamutse G., Woolmore J., Pye E., Partridge J., Boggild M., Young C., et al. Vitamin D receptor gene polymorphism is associated with reduced disability in multiple sclerosis. Mult Scler 14 (2008) 1280-1283
73. Partridge J.M., Partridge J.M., Weatherby S.J., Woolmore J.A., Highland D.J., Fryer A.A., et al. Susceptibility and outcome in MS: associations with polymorphisms in pigmentation-related genes. Neurology 62 (2004) 2323-2325
74. Dwyer T., van der Mei I., Ponsonby A.L., Taylor B.V., Stankovich J., McKay J.D., et al. Melanocortin 1 receptor genotype, past environmental sun exposure, and risk of multiple sclerosis. Neurology 71 (2008) 583-589
75. Swank R.L., Lerstad O., Strøm A., and Backer J. Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. N Engl J Med 246 (1952) 722-728
76. Westlund K. Distribution and mortality time trend of multiple sclerosis and some other diseases in Norway. Acta Neurol Scand 46 (1970) 455-483
77. Feskanich D., Willett W.C., and Colditz G.A. Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women. Am J Clin Nutr 77 (2003) 504-511
78. Goldberg P., Fleming M.C., and Picard E.H. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 21 (1986) 193-200
79. Nordvik I., Myhr K.M., Nyland H., and Bjerve K.S. Effect of dietary advice and n - 3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 102 (2000) 143-149
80. Kimball S.M., Ursell M.R., O'Connor P., and Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 86 (2007) 645-651
81. Achiron A., Barak Y., Miron S., Izhak Y., Faibel M., and Edelstein S. Alfacalcidol treatment in multiple sclerosis. Clin Neuropharmacol 26 (2003) 53
82. Wingerchuk D.M., Lesaux J., Rice G.P., Kremenchutzky M., and Ebers G.C. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 76 (2005) 1294-1296